India, Oct. 15 -- Syngene International, a global contract research, development, and manufacturing organization (CRDMO), has announced site upgrades to accelerate drug discovery and development, helping clients bring novel therapies to market faster.

The investments included a dedicated, state-of-the-art peptide laboratory in Bengaluru and the integration of advanced automation across DMPK (Drug Metabolism and Pharmacokinetics) and Direct-to-Biology (D2B) workflows in Hyderabad- boosting scalability, cost-efficiency, and data quality to accelerate therapeutic innovation.

The dedicated peptide laboratory is designed to produce a wide range of molecules, including linear peptides, cyclic peptides, and peptide-drug conjugates, and support...